These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33438180)

  • 1. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.
    Borghi C; Domienik-Karłowicz J; Tykarski A; Widecka K; Filipiak KJ; Jaguszewski MJ; Narkiewicz K; Mancia G
    Cardiol J; 2021; 28(1):1-14. PubMed ID: 33438180
    [No Abstract]   [Full Text] [Related]  

  • 2. Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update.
    Borghi C; Domienik-Karłowicz J; Tykarski A; Filipiak KJ; Jaguszewski MJ; Narkiewicz K; Barylski M; Mamcarz A; Wolf J; Mancia G
    Cardiol J; 2024; 31(1):1-14. PubMed ID: 38155566
    [No Abstract]   [Full Text] [Related]  

  • 3. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk.
    Borghi C; Tykarski A; Widecka K; Filipiak KJ; Domienik-Karłowicz J; Kostka-Jeziorny K; Varga A; Jaguszewski M; Narkiewicz K; Mancia G
    Cardiol J; 2018; 25(5):545-563. PubMed ID: 30394510
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperuricemia, gout, and cardiovascular disease: an update.
    Abeles AM
    Curr Rheumatol Rep; 2015 Mar; 17(3):13. PubMed ID: 25740704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperuricemia as a risk factor for cardiovascular disease: clinical review.
    Gudiño Gomezjurado Á
    Medwave; 2016 Nov; 16(10):e6606. PubMed ID: 27922586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on gout and hyperuricemia.
    Baker JF; Schumacher HR
    Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperuricemia, gout and cardiovascular diseases].
    Murray K; Burkard T
    Ther Umsch; 2016; 73(3):141-6. PubMed ID: 27008446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert consensus on management of metabolic disease in Chinese liver transplant recipients.
    Shen T; Zhuang L; Sun XD; Qi XS; Wang ZH; Li RD; Chang WX; Yang JY; Yang Y; Zheng SS; Xu X
    World J Gastroenterol; 2020 Jul; 26(27):3851-3864. PubMed ID: 32774062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice].
    Fomin VV; Morosova TE; Tsurko VV
    Ter Arkh; 2019 Dec; 91(12):75-83. PubMed ID: 32598593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of hyperuricemia in occupational health: with reference to "guidelines for the management of hyperuricemia and gout"].
    Nakajima H
    Sangyo Eiseigaku Zasshi; 2003 Jan; 45(1):12-9. PubMed ID: 12624869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperuricemia and cardiovascular continuum].
    Larina VN; Bart BIa; Larin VG; Donskov AS
    Klin Med (Mosk); 2013; 91(1):11-5. PubMed ID: 23659064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature.
    van Durme C; van Echteld IA; Falzon L; Aletaha D; van der Heijde DM; Landewé RB
    J Rheumatol Suppl; 2014 Sep; 92():9-14. PubMed ID: 25180123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease.
    Perez-Ruiz F; Becker MA
    Curr Med Res Opin; 2015; 31 Suppl 2():9-14. PubMed ID: 26414731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gout and cardiovascular risk].
    Němec P
    Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet?
    Gaffo AL; Saag KG
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):1-6. PubMed ID: 22204636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
    Das SR; Everett BM; Birtcher KK; Brown JM; Januzzi JL; Kalyani RR; Kosiborod M; Magwire M; Morris PB; Neumiller JJ; Sperling LS
    J Am Coll Cardiol; 2020 Sep; 76(9):1117-1145. PubMed ID: 32771263
    [No Abstract]   [Full Text] [Related]  

  • 17. Hyperuricemia and Cardiovascular Disease: What is Left to Prove?
    Winter WE
    Metab Syndr Relat Disord; 2017 Feb; 15(1):1-2. PubMed ID: 27824511
    [No Abstract]   [Full Text] [Related]  

  • 18. Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study.
    Nossent J; Raymond W; Divitini M; Knuiman M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):256. PubMed ID: 27978810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperuricemia in hypertension].
    Tatsuno I; Saito Y
    Nihon Rinsho; 2001 May; 59(5):967-72. PubMed ID: 11392000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperuricemia and cardiovascular risk: myth or fact?].
    Fernández-Llama P; Calero F
    Hipertens Riesgo Vasc; 2015; 32(4):131-2. PubMed ID: 26486460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.